Latest Gmp Manufacturing News

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Bioxyne Limited posted a record $21.3 million revenue in Q3 FY26, driven by strong demand for medicinal cannabis and psychedelics. The company secured a manufacturing agreement with Aurora Cannabis and initial orders for GMP psilocybin capsules, reaffirming FY26 guidance.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

Little Green Pharma reports record quarterly revenue and announces a transformative merger with Cannatrek, creating a leading vertically integrated medicinal cannabis group with strong European growth prospects.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.